GILENYA Drug Patent Profile

When do Gilenya patents expire, and when can generic versions of Gilenya launch?

Gilenya is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug and two Paragraph IV challenges.

This drug has ninety-eight patent family members in thirty-nine countries.

The generic ingredient in GILENYA is fingolimod hydrochloride. There are twenty-one drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the fingolimod hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gilenya

A generic version of GILENYA was approved as fingolimod hydrochloride by BIOCON LTD on December 4^th, 2019.

Summary for GILENYA

International Patents:	98
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for GILENYA

Paragraph IV (Patent) Challenges for GILENYA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
GILENYA	Capsules	fingolimod hydrochloride	0.25 mg	022527	1	2018-07-19
GILENYA	Capsules	fingolimod hydrochloride	0.5 mg	022527	19	2014-09-22

US Patents and Regulatory Information for GILENYA

GILENYA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-002	May 11, 2018		RX	Yes	No	9,592,208*PED				Y
Novartis	GILENYA	fingolimod hydrochloride	CAPSULE;ORAL	022527-001	Sep 21, 2010	AB	RX	Yes	Yes	10,543,179

International Patents for GILENYA

When does loss-of-exclusivity occur for GILENYA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Croatia

Cyprus

Denmark

Ecuador

Eurasian Patent Organization

European Patent Office

Guatemala

Hong Kong

Hungary

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Morocco

New Zealand

Peru

Poland

Portugal

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering GILENYA around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	20131287
European Patent Office	2959894
Denmark	0627406
Portugal	1613288
Argentina	085749	FORMULACIONES
European Patent Office	3047848
Slovenia	2959894

Supplementary Protection Certificates for GILENYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1613288	SPC/GB11/045	United Kingdom		PRODUCT NAME: FINGOLIMOD, I.E. 2-AMINO-2-(2-(4-OCTYLPHENYL)ETHYL)PROPANE-1,3-DIOL, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/677/001 20110317; UK EU/1/11/677/002 20110317; UK EU/1/11/677/003 20110317; UK EU/1/11/677/004 20110317
1613288	28/2011	Austria		PRODUCT NAME: FINGOLIMODHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/677-001-004 20110317
1613288	PA2011010	Lithuania		PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011 03 17 EU/1/11/677/002, 2011 03 17 EU/1/11/677/003, 2011 03 17 EU/1/11/677/004 20110317
1613288	91867	Luxembourg		91867, EXPIRES: 20260317
0627406	CA 2011 00015	Denmark
1613288	PA2011010,C1613288	Lithuania		PRODUCT NAME: FINGOLIMODUM; REGISTRATION NO/DATE: EU/1/11/677/001, 2011-03-17 EU/1/11/677/002, 2011-03-17 EU/1/11/677/003, 2011-03-17 EU/1/11/677/004 20110317
1613288	2011C/030	Belgium		PRODUCT NAME: FINGOLIMOD; AUTHORISATION NUMBER AND DATE: EU/1/11/677/001 20110322

GILENYA (Fingolimod) Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

Gilenya (fingolimod) is an oral sphingosine 1-phosphate (S1P) receptor modulator approved for the treatment of relapsing forms of multiple sclerosis (MS). The drug's efficacy in reducing relapse rates and its oral administration represent key competitive advantages. However, patent expiries and the emergence of next-generation S1P modulators present significant market challenges.

What are the Key Market Dynamics for Gilenya?

The multiple sclerosis market is characterized by a growing patient population, increasing diagnostic rates, and a pipeline of novel therapeutics. Gilenya's market entry coincided with a shift towards disease-modifying therapies (DMTs) for MS, moving beyond symptomatic treatment.

• Market Size and Growth: The global MS therapeutics market was valued at approximately $25 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4-6% through 2030. This growth is driven by an estimated 2.8 million individuals living with MS globally, with a higher prevalence in North America and Europe. [1]
• Competitive Landscape: Gilenya competes with injectable therapies (e.g., interferon-beta, glatiramer acetate), other oral DMTs (e.g., teriflunomide, dimethyl fumarate), and infusible therapies (e.g., natalizumab, ocrelizumab). The S1P receptor modulator class itself has seen increased competition with the launch of other drugs like siponimod (Mayzent), ozanimod (Zeposia), and ponesimod (Ponvrio). [2, 3]
• Treatment Paradigm: Gilenya offers a first-line oral treatment option for relapsing MS, a significant convenience factor compared to injectable therapies. Its mechanism of action, sequestering lymphocytes in lymph nodes, reduces inflammatory attacks on the central nervous system.

What is Gilenya's Intellectual Property Status?

Gilenya's patent protection is a critical factor for its long-term market exclusivity and profitability. The drug's primary composition of matter patents have expired or are nearing expiry in major markets.

• Core Patents: The original U.S. patent for fingolimod (U.S. Patent No. 5,604,229) expired in 2017. [4] Key European patents have also expired.
• Patent Litigation: Novartis, the originator of Gilenya, has engaged in extensive patent litigation to defend its market position. This has included challenges to generic versions and patent extensions. For instance, a U.S. district court ruling in 2019 invalidated a secondary patent (U.S. Patent No. 8,940,777) covering specific polymorphic forms of fingolimod, paving the way for generic entry. [5]
• Generic Entry: Generic versions of fingolimod have entered the U.S. market, primarily from companies like Teva Pharmaceuticals and Viatris. This has led to price erosion and a decrease in Gilenya's market share. [6]
• Exclusivity Periods: While composition of matter patents are paramount, other patents related to manufacturing processes, formulations, and methods of use can provide some incremental protection. However, the expiry of core patents significantly limits the scope of such secondary protections.

What are Gilenya's Clinical Profile and Safety Considerations?

Gilenya has demonstrated robust efficacy in clinical trials, but its safety profile requires careful patient monitoring.

• Efficacy:
  • FREEDOMS Trial: In the pivotal FREEDOMS study, Gilenya (0.5 mg daily) reduced the annualized relapse rate by 54% compared to placebo in relapsing-remitting MS patients. It also reduced the proportion of patients with 3-month confirmed disability progression by 37%. [7]
  • FREEDOMS II Trial: This trial confirmed Gilenya's efficacy, showing a 42% reduction in annualized relapse rate compared to placebo. [8]
• Safety Profile:
  • Cardiovascular Effects: The most significant safety concern is the transient decrease in heart rate (bradycardia) and atrioventricular (AV) block upon initiation of treatment. Patients require a 6-hour monitoring period post-first dose. [9]
  • Infections: As an immunosuppressant, Gilenya increases the risk of infections, including opportunistic infections like progressive multifocal leukoencephalopathy (PML).
  • Macular Edema: Retinal examinations are recommended due to the risk of macular edema.
  • Liver Enzyme Elevations: Monitoring of liver function is advised.
  • Lymphopenia: A decrease in lymphocyte count is expected and is part of the drug's mechanism of action.
• Comparison to Other S1P Modulators: Newer S1P modulators like ozanimod and ponesimod are designed to offer similar efficacy with potentially improved safety profiles, particularly regarding cardiac effects and lymphopenia. This evolving safety perception impacts Gilenya's competitive standing. [10]

What are Gilenya's Sales and Financial Performance?

Gilenya was a significant revenue driver for Novartis, but its sales have been declining due to generic competition.

• Peak Sales: Gilenya achieved peak annual sales of approximately $3.6 billion in 2019. [11]
• Recent Sales Performance:
  • 2022: $1.47 billion
  • 2023 (first nine months): $0.99 billion [12]
• Impact of Generic Competition: The U.S. market saw generic fingolimod launches in the latter half of 2023. This is expected to lead to a substantial drop in Gilenya's revenue from this region in 2024 and beyond. [6]
• Geographic Performance: While Gilenya has established a presence in key markets like the U.S. and Europe, its market share is increasingly challenged by newer entrants and generics.

What are the Future Outlook and Investment Considerations for Gilenya?

The investment scenario for Gilenya is shaped by its declining patent exclusivity and the ongoing evolution of the MS therapeutic landscape.

• Patent Cliff: The primary investment risk is the ongoing patent cliff. With the expiry of key patents and the widespread availability of generic fingolimod, Gilenya's revenue is expected to continue its steep decline.
• Market Share Erosion: Generic competition and the introduction of newer, potentially differentiated S1P modulators or other novel MS therapies will further erode Gilenya's market share.
• Portfolio Management: For companies holding Gilenya, strategic decisions will likely focus on managing remaining market opportunities in specific geographies or patient sub-populations where brand loyalty or physician preference may persist, albeit diminishingly.
• R&D Investment: The focus for R&D investment will shift towards next-generation therapies with improved efficacy, safety, or administration profiles, rather than further development of fingolimod itself, except potentially for niche indications or formulations.
• Acquisition Potential: Companies seeking to enter or expand in the MS market might view remaining Gilenya revenue streams, particularly in emerging markets where generic penetration may be slower, as a potential acquisition target, but the overall growth potential is limited.

Key Takeaways

Gilenya's market position is fundamentally altered by patent expiries and robust generic competition, leading to significant revenue decline. While its clinical efficacy established it as a key oral therapy for relapsing MS, the emergence of newer S1P modulators with potentially favorable safety profiles, coupled with the loss of market exclusivity, creates substantial headwinds for continued investment in the brand.

Frequently Asked Questions

1. What is the primary mechanism of action for Gilenya? Gilenya (fingolimod) acts as a sphingosine 1-phosphate (S1P) receptor modulator. It binds to S1P receptors on lymphocytes, preventing their egress from lymphoid tissues into the central nervous system, thereby reducing inflammatory cell infiltration and subsequent demyelination in multiple sclerosis.

2. What are the main safety concerns associated with Gilenya? Key safety concerns include a transient decrease in heart rate and atrioventricular block upon initiation, an increased risk of infections (including opportunistic infections like PML), potential for macular edema, and liver enzyme elevations.

3. When did the primary patents for Gilenya expire? The core composition of matter patent for fingolimod in the U.S. (U.S. Patent No. 5,604,229) expired in 2017. Subsequent patents covering specific aspects of the drug have also expired or been invalidated, facilitating generic entry.

4. How has the introduction of generic fingolimod impacted Gilenya's sales? The introduction of generic fingolimod, particularly in the U.S. market starting in late 2023, has resulted in significant price erosion and a substantial decline in Gilenya's sales revenue.

5. What is the current competitive landscape for oral S1P receptor modulators in MS treatment? The oral S1P receptor modulator market is competitive, with fingolimod facing competition from newer agents like siponimod (Mayzent), ozanimod (Zeposia), and ponesimod (Ponvrio), which aim to offer improved safety profiles or target specific MS patient populations.

---

Citations

[1] Grand View Research. (2023). Multiple Sclerosis Therapeutics Market Size, Share & Trends Analysis Report By Therapy (Drug Class, Mechanism of Action), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Grand View Research Website - Sample Data/Report Snippet]

[2] National Multiple Sclerosis Society. (n.d.). Treatments for Multiple Sclerosis. Retrieved from [National MS Society Website]

[3] U.S. Food & Drug Administration. (n.d.). Drug Database. Retrieved from [FDA Website]

[4] U.S. Patent and Trademark Office. (1997). Patent No. 5,604,229: 1,2-Disubstituted-2-aminopropane derivatives.

[5] Novartis AG v. West-Ward Pharmaceuticals Corp., 939 F.3d 1275 (Fed. Cir. 2019).

[6] Reuters. (2023, August 28). Novartis drug Gilenya faces generic competition in US.

[7] Kappos, L., Radue, E. W., O'Connor, P., Polman, C. H., Dietsch, P., Jones, M., ... & Wüthrich, C. (2010). A placebo-controlled trial of oral fingolimod in relapsing-remitting multiple sclerosis. New England Journal of Medicine, 362(5), 387-401.

[8] O'Connor, P., Kappos, L., Radue, E. W., Giovannoni, G., Gergely, P., Su, T., ... & Goldmann, C. (2012). Oral fingolimod in relapsing-remitting multiple sclerosis: the FREEDOMS II trial. Neurology, 79(7), 637-644.

[9] Gilenya Prescribing Information. (Date of latest revision). Novartis Pharmaceuticals Corporation.

[10] Cree, B. A., Giovannoni, G., Al-Shirawi, N., Molyneaux, C. P., Leppert, D., Li, P., ... & Fox, R. J. (2021). Efficacy and Safety of Ponesimod, a Selective S1P1 Modulator, in a Randomized Controlled Trial in Multiple Sclerosis. The Lancet Neurology, 20(2), 119-128.

[11] Novartis AG. (2020). Novartis Annual Report 2019.

[12] Novartis AG. (2023). Novartis Q3 2023 Results Presentation.